Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model for Antisense Drug Development
Author Information
Author(s): Wu Bo, Benrashid Ehsan, Lu Peijuan, Cloer Caryn, Zillmer Allen, Shaban Mona, Lu Qi Long
Primary Institution: McColl-Lockwood Laboratory for Muscular Dystrophy Research, Carolinas Medical Center
Hypothesis
Can targeted exon skipping of human dystrophin be effectively achieved in a transgenic mouse model?
Conclusion
The study successfully demonstrated over 70% efficiency of targeted human dystrophin exon skipping in vivo using a transgenic mouse model.
Supporting Evidence
- Antisense therapy has shown potential for treating Duchenne muscular dystrophy.
- The study achieved over 70% efficiency of targeted exon skipping in a mouse model.
- Results suggest that a combination of in vitro and in vivo testing is crucial for selecting effective antisense oligonucleotides.
- Vivo-PMO was effective in delivering the oligonucleotides systemically.
- High levels of exon skipping were observed in both skeletal and cardiac muscles.
Takeaway
Researchers found a way to skip parts of a gene that causes a muscle disease in mice, which could help develop new treatments for kids with that disease.
Methodology
The study used a combination of in vitro cell cultures and a transgenic mouse model to evaluate the efficacy of antisense oligonucleotides for skipping human dystrophin exons.
Potential Biases
Potential bias in selecting antisense oligonucleotides based on in vitro results that may not correlate with in vivo efficacy.
Limitations
The study's findings may not fully translate to human patients due to differences between mouse and human muscle biology.
Participant Demographics
The study involved transgenic mice carrying the full-length human dystrophin gene.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website